On Tuesday, Shares of Ford Motor Co. (NYSE:F), gained 0.41% to $14.81.
Ford Motor Company U.S. sales totaled 213,938 vehicles last month, up 13 percent from a year ago. Retail sales results were up 13 percent with 154,036 vehicles sold – for the company’s best October sales performance since 2004.
Retail sales raised across the product portfolio, with cars up 8 percent, with both trucks and SUVs rising 15 percent.
“Strong demand for our vehicles offered another double-digit sales improvement in October, and Ford vehicles posted all-time record average transaction pricing of $34,600 per vehicle,” said Mark LaNeve, Ford vice president, U.S. Marketing, Sales and Service. “Gains in our truck business were especially strong, with F-Series delivering its fourth straight month of sales gains and its best October retail levels since 2004.”
Ford vehicle average transaction prices rose $1,800 as contrast to a year ago – the largest gain among any major automaker.
Ford Motor Company manufactures and distributes automobiles worldwide. The company operates through two sectors, Automotive and Financial Services. The Automotive sector develops, manufactures, distributes, and services vehicles, parts, and accessories. It offers vehicles primarily under the Ford and Lincoln brand names.
Shares of Pfizer Inc. (NYSE:PFE), declined -0.26% to $34.97, during its last trading session.
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, recently declared that the Phase IIb study LATTE 2 (NCT02120352) met its primary endpoint at 32 weeks. These results show that the investigational, long acting, injectable formulations of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen) were comparable in maintaining viral suppression rates to a three drug oral regimen of investigational cabotegravir and two nucleoside reverse transcriptase inhibitors (NRTIs). The 32 week results of LATTE 2 will be presented at a forthcoming scientific conference. ViiV Healthcare and Janssen Sciences Ireland UC (Janssen) are collaborating to conduct LATTE 2.
Patients switching to CAB LA and RPV LA administered Q4W stated more adverse events (AEs) leading to withdrawal (5%; n=6) contrast with those receiving an injection Q8W (2%; n=2) or who continued on oral CAB + NRTIs (2%, n=1). The most common adverse event (AE) stated by patients was injection site pain (93% of injection recipients). Two patients in the Q8W arm (none in the Q4W arm) withdrew for injection intolerance. Two patients met protocol defined virologic failure criteria, Q8W (n=1), oral (n=1); neither patient had evidence of resistance at failure.
ViiV Healthcare is committed to identifying new therapeutic options for physicians and people living with HIV. These initial phase IIb data investigating long-acting cabotegravir and rilpivirine are promising and build on the results we have seen to date. We look forward to seeing further results as we move into phase III, said John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.
Finally, Shares of Citrix Systems, Inc. (NASDAQ:CTXS), ended its last trade with -1.12% loss, and closed at $62.66.
Citrix Systems, declared that executives will attend four forthcoming investor conferences.
Eduardo Fleites, vice president, investor relations, will present at the Bernstein Technology Innovation Summit in San Francisco on November 5 at 6:15 p.m. Eastern.
Eduardo Fleites, vice president, investor relations, will meet one-on-one with investors at the Mizuho Technology Corporate Access Day in New York on November 10.
Michael Cristinziano, vice president, planned development, will meet one-on-one with investors at the RBC Capital Markets’ Technology, Internet, Media and Telecommunications Conference in New York on November 11.
Citrix Systems, Inc. provides virtualization, mobility administration, networking, and Software as a Service solutions worldwide. The company’s Enterprise and Service Provider division offers XenMobile Enterprise, a solution to manage mobile devices, apps, and data; XenDesktop, a desktop virtualization system that gives customers the flexibility to deliver desktops and applications as cloud services; Citrix XenApp that allows Windows applications to be delivered as cloud services to Android and iOS mobile devices, Macs, PCs, and thin clients; and Citrix Workspace Suite, a business mobility solution that delivers the user experience for any app or desktop.
This article is published by www.stocksnewswire.com. The content included in this article is just for informational purposes only. Stocksnewswire.com takes sensible consideration to ensure that the data given in this article is up to date and accurate. The news, prices, opinions, research, analysis, and other information published in this article are obtained from sources believed to be reliable.
Neither Stocksnewswire.com nor any of Stocksnewswire.com partners make any representation or guarantee as to the fulfillment or precision of the information contained in this article.
Investors must consult their own additional due diligence with any potential investment or highlighted company before making any decision on behalf of information offered by Stocksnewswire.com.
Information contained in this article may contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long-term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
You may also like
Facebook, Inc. (NASDAQ:FB) Earned “Buy” Rating Fro…Investor’s Alert – Rite Aid Corporatio…Traders Alert – Ford Motor Co., (NYSE:F), Ki…News Buzz: Whole Foods Market, (NASDAQ:WFM), Micro…Traders Recap – Microsoft Corporation, (NASD…Eye-Catching Stocks – Chesapeake Energy Corp…Worth Watching Stocks – Freeport-McMoRan, (N…Hot Stocks to Keep Your Eyes on – Apple, (NA…News Recap – FireEye, (NASDAQ:FEYE), Avon Pr…